27th Jun 2014 12:10
LONDON (Alliance News) - ImmuPharma PLC Friday said its UREKA subsidiary has set up its own research team within laboratories at the Institut Européen de Chimie et Biologie, a network of 15 international and multi-disciplinary research teams.
The company said that UREKA has set up the team as it continues its work into peptides. ImmuPharma recently filed patents covering peptide technology platform Urelix. It has highlighted type 2 diabetes as the first area it will target, and thinks that blocking virus entry into cells could be a further area that could be further researched.
"The utilisation within our own premises, with the potential financial support of the French Aquitaine region, will be integral to our ongoing strategy of keeping [research and development] costs low while focusing more on applied research," President and Chief Science Officer Zimmer said in a statement.
"Importantly, the new discovery represents a powerful applied research engine to discover innovative and powerful medicines, mirroring the success ImmuPharma has already demonstrated with our patented peptide for Lupuzor," Zimmer added.
The Institut Européen de Chimie et Biologie is a collaboration placed under the authority of research organisation Centre National de la Recherche Scientifique, French biomedical and public health research institution Institut National de la Santé et de la Recherche Médicale, and the University of Bordeaux, in France.
ImmuPharma shares were Friday quoted at 51.69 pence, up 4.9%.
By Samuel Agini; [email protected]; @samuelagini
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Immupharma